14.92
-0.08(-0.53%)
Currency In USD
| Previous Close | 15 |
| Open | 14.95 |
| Day High | 15.17 |
| Day Low | 14.5 |
| 52-Week High | 19.41 |
| 52-Week Low | 8.26 |
| Volume | 1.7M |
| Average Volume | 1.41M |
| Market Cap | 1.28B |
| PE | -8.24 |
| EPS | -1.81 |
| Moving Average 50 Days | 14.87 |
| Moving Average 200 Days | 12.71 |
| Change | -0.08 |
If you invested $1000 in Liquidia Corporation (LQDA) since IPO date, it would be worth $1,344.14 as of June 01, 2025 at a share price of $14.92. Whereas If you bought $1000 worth of Liquidia Corporation (LQDA) shares 5 years ago, it would be worth $1,555.79 as of June 01, 2025 at a share price of $14.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company’s Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Busine
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
GlobeNewswire Inc.
May 23, 2025 6:28 PM GMT
FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effortDemonstrated tolerabi
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
GlobeNewswire Inc.
May 12, 2025 10:00 AM GMT
New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA‘782 patent claims same general subject matter